In the MolPros project, we will validate a set of genetic markers (SNPs) that can be used to identify patients with high PC risk.
In a prospective collaboration with urologists and general practitioners we will assess the safety and compliance of excluding men with low genetic PC risk from further PSA testing, and implement this new strategy in the clinic.
To prevent overtreatment of PC, we will identify a new set of genetic markers that can lead to separation of aggressive cases from non-aggressive. Biomarker identification will be based on our large unique prostate cancer biobank with clinical annotation as well as front-end technologies in our new Next Generation Sequencing (NGS) center, and among international collaborators.
We will identify markers for aggressiveness of prostate cancer at genomic, transcriptomic and epigenomic levels, using novel integrative systems biology tools (developed and marketed by the company CLC bio) and clinical end-points. Finally, we will validate the markers internationally and implement them in the clinic using nomograms for ease of daily use.
To evaluate the safety and usefulness of SNP-based genetic tests for individual PC risk prediction by prospective testing in a clinical setting incl. urology departments and general practitioners
To establish a follow-up control program for high-risk individuals and evaluate the safety, compliance, and effect of excluding low-risk individuals from repeated PSA testing (high-risk cases will be cared for in a new PC prevention clinic)
To identify new markers for PC aggressiveness using new NGS technologies, microarray analyses, and one of the world’s largest biobanks for PC tissue with clinical annotation
To validate the new molecular markers in large independent patient cohorts (single markers, combinations of multiple markers (signatures)), and incorporate them into risk algorithms
To utilize the data generated to invent, design and develop novel bioinformatics software tools critical for this project as well as for NGS and microarray data analysis in general, and for systems biology specifically (the company CLC bio will market these tools)
To combine the clinical, histopathological and molecular risk parameters into a nomogram for PC risk and implement this in a prospective clinical study at urology departments in Denmark